Abstract

The goal of this study is to enhance the anti-tumor activity of VNP2OOO9, a genetically engineered Salmonella typhimurium, by arming the bacteria with cytokines and prod rug converting enzymes. IL2, TRAIL, DT- diaphorase, cytochrome p450 2B1, or cytosine deaminase will be cloned and expressed in VNP2OOO9 and anti-tumor activity of these clones will be evaluated in murine tumor models. In order to enhance the secretion of these therapeutic proteins from VNP2OOO9, various secretion systems including bacteriocin release peptide and ompA signal peptide will be used.

Proposed Commercial Applications

The products discovered from this study, if successful, may be used for the treatment of cancer in patients.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44CA077963-03
Application #
6342093
Study Section
Special Emphasis Panel (ZRG1-SSS-1 (02))
Program Officer
Wolpert, Mary K
Project Start
1998-03-01
Project End
2001-12-31
Budget Start
2001-01-01
Budget End
2001-12-31
Support Year
3
Fiscal Year
2001
Total Cost
$375,000
Indirect Cost

  Institution

Name
Vion Pharmaceuticals, Inc.
Department
Type
DUNS #
City
New Haven
State
CT
Country
United States
Zip Code
06511